Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

742 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).
Ulrich S, Speich R, Domenighetti G, Geiser T, Aubert JD, Rochat T, Huber L, Treder U, Fischler M. Ulrich S, et al. Swiss Med Wkly. 2007 Oct 20;137(41-42):573-80. doi: 10.4414/smw.2007.11819. Swiss Med Wkly. 2007. PMID: 17990150 Free article. Clinical Trial.
Pulmonary hypertension in Switzerland: treatment and clinical course.
Fischler M, Speich R, Dorschner L, Nicod L, Domenighetti G, Tamm M, Rochat T, Aubert JD, Ulrich S; Swiss Society for Pulmonary Hypertension. Fischler M, et al. Among authors: ulrich s. Swiss Med Wkly. 2008 Jun 28;138(25-26):371-8. doi: 10.4414/smw.2008.11914. Swiss Med Wkly. 2008. PMID: 18587689 Free article.
MicroRNAs and pulmonary hypertension.
Brock M, Ulrich S, Huber LC. Brock M, et al. Among authors: ulrich s. Eur Respir J. 2014 Jan;43(1):313-4. doi: 10.1183/09031936.00039113. Eur Respir J. 2014. PMID: 24381328 Free article. No abstract available.
Long-term data from the Swiss pulmonary hypertension registry.
Mueller-Mottet S, Stricker H, Domenighetti G, Azzola A, Geiser T, Schwerzmann M, Weilenmann D, Schoch O, Fellrath JM, Rochat T, Lador F, Beghetti M, Nicod L, Aubert JD, Popov V, Speich R, Keusch S, Hasler E, Huber LC, Grendelmeier P, Tamm M, Ulrich S. Mueller-Mottet S, et al. Among authors: ulrich s. Respiration. 2015;89(2):127-40. doi: 10.1159/000370125. Epub 2015 Jan 31. Respiration. 2015. PMID: 25661477 Free article.
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators. Ghofrani HA, et al. Lancet Respir Med. 2017 Oct;5(10):785-794. doi: 10.1016/S2213-2600(17)30305-3. Epub 2017 Sep 11. Lancet Respir Med. 2017. PMID: 28919201 Retracted and republished. Retracted. Clinical Trial.
742 results